The combination of quantitative DW-MRI and [89Zr]Zr-trastuzumab PET has the potential to offer a clinically superior approach for understanding tumor heterogeneity in patients with metastatic HER2-positive breast cancer. This evidence concerns the gene ERBB2 and neoplasm.